Poston Robert S, Husain Shahid, Sorce Damian, Stanford Ellieen, Kusne Shimon, Wagener Margaret, Griffith Bartley P, Kormos Robert L
Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
J Heart Lung Transplant. 2003 Aug;22(8):914-21. doi: 10.1016/s1053-2498(02)00645-9.
Patients who have ventricular assist devices (VADs) and experience bloodstream infection (BSI) have high mortality. We addressed 2 questions raised by the United Network for Organ Sharing (UNOS) priority policy for this problem: 1) Are organs wasted on this ultra-high-risk group? 2) Can device-related BSI be differentiated from transient BSI?
Patients with VADs who underwent heart transplantation from 1987 to 2001, who had BSI during VAD support, and who had positive cultures at VAD explant (device-related BSI, n = 10) were compared with those with negative cultures at explant (non-device-related BSI, n = 11).
Patients with device-related BSI had an 80% (8/10) rate of persistent bacteremia; 30 days and 1 year after transplantation, mortality was 14% and 26%, respectively. Non-device-related BSI (n = 11) persisted in 18% (2/11); peri-operative and 1-year mortalities were 9% and 13%. Duration of VAD support predicted infection (132 vs 48 days, p < 0.001); hypo-albuminemia (2.9 +/- 0.5 mg/dl vs 3.3 +/- 0.8 mg/dl, p < 0.05), and a resistant organism predicted a device-related BSI. These patients had increased intubation requirements and had increased creatinine concentration during the first post-operative week, with no difference in liver function, blood loss, transfusions (packed red blood cells, fresh frozen plasma, or platelets), or hemodynamic stability vs patients with non-device BSI. Despite decreased immunosuppression, we found no difference in acute rejection events with device-related BSI. Re-infection with the pre-operative organism occurred in only 1 patient per group.
These data suggest that urgent (Status 1A) cardiac transplantation is effective in stable patients with device-related BSI, and these data support the current UNOS policy. However, an extra-device source of BSI should be excluded by considering the isolated organism, the baseline nutritional status, and other risk factors.
植入心室辅助装置(VAD)并发生血流感染(BSI)的患者死亡率很高。我们探讨了器官共享联合网络(UNOS)针对此问题的优先政策提出的两个问题:1)对于这个超高风险群体,器官是否被浪费了?2)与装置相关的BSI能否与短暂性BSI区分开来?
对1987年至2001年期间接受心脏移植、在VAD支持期间发生BSI且VAD取出时培养结果呈阳性(与装置相关的BSI,n = 10)的VAD患者与取出时培养结果呈阴性(与装置无关的BSI,n = 11)的患者进行比较。
与装置相关的BSI患者持续性菌血症发生率为80%(8/10);移植后30天和1年的死亡率分别为14%和26%。与装置无关的BSI(n = 11)持续性发生率为18%(2/11);围手术期和1年死亡率分别为9%和13%。VAD支持时间可预测感染情况(132天对48天,p < 0.001);低白蛋白血症(2.9±0.5mg/dl对3.3±0.8mg/dl,p < 0.05)以及耐药菌可预测与装置相关的BSI。这些患者术后第一周插管需求增加,肌酐浓度升高,与非装置相关BSI患者相比,肝功能、失血量、输血(浓缩红细胞、新鲜冰冻血浆或血小板)或血流动力学稳定性无差异。尽管免疫抑制有所降低,但我们发现与装置相关的BSI患者在急性排斥反应事件方面无差异。每组仅1例患者发生术前感染病原体的再次感染。
这些数据表明,紧急(1A类)心脏移植对患有与装置相关的BSI的稳定患者有效,这些数据支持当前的UNOS政策。然而,应通过考虑分离出的病原体、基线营养状况和其他风险因素来排除BSI的装置外来源。